DexCom 254.48 p/e ratio hints to a stock price bubble

DXCM STOCK PRICE CHART HAS LATELY FORMED A POSSIBLE DOUBLE TOP PATTERN AROUND THE $428.59 DOLLARS PER SHARE.
THE STOCK PRICE HAS INFLATED NEARLY +50% MORE THAN THE HIGH BEFORE Q1 2020 CORRECTION. INFACT, DXCM STOCK PRICE
WAS $302.50 AT HIGH, BEFORE MAKING A LOW AT $191.16. THE STOCK PRICE HAS SINCE THEN, IN ABOUT TWO MONTHS TIME, INFLATED BY MORE THAN 100%
ADDING $237.43 DOLLARS, TO THE STOCK PRICE, AT TIME WHEN THE GLOBAL ECONOMY HAS SHUT DOWN IN RECESSION AND THE UNITED STATES JOB MARKET HAS RECORDED NEARLY
40.0 MLN AMERICANS UNEMPLOYED.
DexCom HAS POSTED NEGATIVE NET INCOME FOR 2016/17/18, MEANING $-65.6 MLN NET INCOME, $-50.2 MLN, $-127.1, ONLY IN 2019 REVENUES HAVE GROWN TO $1.6 BILLION WHILE NET INCOME WAS $101.1 MLN
ONLY RECENTLY THE COMPANY HAS PRICED AN UPSIZE $1.05 BILLION private offering of 0.25% convertible senior notes due 2025M ADDING TO THE 116.28% LONG TERM DEBT/EQUITY RATIO, WITH THE POSSIBILITY
THAT CONVERTIBLE DEBT OBLIGATION, WILL MAKE DILUTED SHAREHOLDERS IN THE FUTURE.
ACCORDING TO OTHER METRICS, 5Y ROI -2.31%, ROA -1.96%, ROE -4.48%, NET PROFIT MARGIN -2.24%, SEEMS THE STOCK PRICE HAD BEEN SPECTACULARLY INFLATED AND OVERPRICED.

THE CHART FORMED A DOUBLE TOP $428.0 DOLLAR PRICE, WHERE THE $405.25 STANDING BELOW THE TENKAN LINE.
POSSIBLE TO SEE THE STOCK PRICE GOING DOWN TO TEST THE KIJUN LINE PRICE $366.15, -9.5% CORRECTION